Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancersJustina X. Caushi, Kellie N. Smith, Taha Merghoub et al.|Nature|2021Cited by 546
SARS-CoV-2 messenger RNA vaccine antibody response and reactogenicity in heart and lung transplant recipientsAndrew M. Hallett, Errol L. Bush, Ross S. Greenberg et al.|The Journal of Heart and Lung Transplantation|2021Cited by 65
Impact of recipient age on mortality among Cytomegalovirus (CMV)-seronegative lung transplant recipients with CMV-seropositive donorsSara Belga, William A. Werbel, Sarah Hussain et al.|The Journal of Heart and Lung Transplantation|2023Cited by 2
Trends over Time in Practice and Outcomes of Lung Transplantation in Recipients With Human Immunodeficiency VirusZeba Nauroz, Mary G. Bowring, Jessica M. Ruck et al.|Transplant Infectious Disease|2025Cited by 2
SARS-CoV-2 Messenger RNA Vaccine Antibody Response and Reactogenicity in Heart and Lung Transplant Recipients: SARS-CoV-2 vaccine response in heart and lung recipientsAndrew M. Hallett, Errol L. Bush, Ross S. Greenberg et al.|The Journal of Heart and Lung Transplantation|2021Cited by 0